Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data. To compare the risk of venous thromboembolism (VTE) among young women for nine combined oral contraceptives (COCs), including progestogens with an as yet unclear risk of VTE such as chlormadinone and nomegestrol, using COCs containing levonorgestrel with current use of the respective COCs were calculated using conditional logistic regression. Venous thromboembolism (VTE), defined as a diagnosis of pulmonary embolism or deep vein thrombosis. Compared with levonorgestrel with low ethinylestradiol (<50 μg), the risk of VTE was increased two-fold for COCs containing dienogest (aOR 2.23, 95% CI 1.77-2.80), cyproterone (aOR 2.15, 95% CI 1.43-3.25
on gynecologic considerations for adolescentsand young women with cardiac conditions:cGynecologic care of adolescent girls and youngwomen with cardiac conditions should occur incollaboration with the patient’s cardiologist.cAdolescent patients and young women with con-genital heart disease may have a high unmet need forcontraception compared with other adolescents.cBecause of the morbidity associated care ofadolescent girls and young women with cardiac condi-tions should occur in collaboration with the patient’scardiologist. For more information, see the USMEC(3); ACOG Practice Bulletin No. 206,Use of HormonalContraception in Women With Coexisting Medical Con-ditions(4); and the American Heart Association’s guid-ance on management of adults with congenital heartdisease (5, 6). For guidance
). The choice between these options depends on patient preferences regarding efficacy, side effects, and cost. * 3.3. For most women, we do not suggest one oral contraceptive over another as initial therapy, as all oral contraceptives appear to be equally effective for hirsutism, and the risk of side effects is low. (2 |⊕⊕OO) * 3.4. For women with hirsutism at higher risk for venous added a recommendation to use lower estrogen-dose OCs with low-risk progestins in women at higher risk for venous thromboembolism (VTE) (e.g., obese, age >39 years). For other women, our approach is the same as in the original guideline: we do not suggest one OC formulation over another. * We made a stronger recommendation against the use of flutamide for hirsutism. * We added a suggestion
for the female/castrate range (~50 ng/dL) and the dashed grey line is the testosterone level in a comparison group of post-operative transgender women (21.7 ng/dL).[49]Estrogens are the major sex hormones in women, and are responsible for the development and maintenance of feminine secondary sexual characteristics, such as breasts, wide hips, and a feminine pattern of fat distribution.[4] Estrogens act that these physiological levels of estradiol are usually unable to suppress testosterone levels into the female range.[1] A 2018 Cochrane review proposal questioned the notion of keeping estradiol levels lower in transgender women, which results in incomplete suppression of testosterone levels and necessitates the addition of antiandrogens.[67] The review proposal noted that high-dose parenteral estradiol is known
is bleeding in post-menopausal women. Transgender men who have any bleeding after the cessation of menses with androgen therapy should be evaluated for age appropriate causes of abnormal uterine bleeding as per cisgender female guidelines.[26] * Adults with a uterus/cervix are advised to have a Pap smear per guidelines (Human papillomavirus infection). Use of testosterone is no exception to this rule Hormone replacement therapy (female-to-male) Masculinizing hormone therapy - WikipediaMasculinizing hormone therapyFrom Wikipedia, the free encyclopedia(Redirected from Hormone replacement therapy (female-to-male))Jump to navigationJump to searchHormone replacement therapyPart of a series on Transgender topics
of VTE in women using low-androgen progestins relative to those using levonorgestrel-containing products. Although no pattern of hepatic globulin changes has been validated as a surrogate marker for thrombosis risk, the overall magnitude of change in various hepatic proteins involved in coagulation is greater with the newer low-androgenic progestins compared to levonorgestrel, leading some experts Healthy Volunteers: Yes Criteria Inclusion Criteria: * Women of reproductive age (18-44 years) in generally good health and with body mass index (BMI) between 18 and 35kg/m2 * Premenopausal, with uterus and at least one ovary intact * Current users (at least 3 months) of combined oral contraception consisting of 0.02 mg (milligram) ethinyl estradiol and 3 mg drospirenone
Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The objective of this study was to investigate the impact of the oral contraceptive YASMIN (containing: drospirenone 3 mg/ethinyl estradiol 30 mcg) in comparison with the oral contraceptive MICROGYNON (containing: levonorgestrel 150 mcg/ethinyl estradiol 30mcg) on factors of blood Criteria Inclusion Criteria: * Clinically normal safety laboratory resultsExclusion Criteria: * Standard contraindications for use of combined oral contraceptives (class label). Including: * Presence or history of thromboembolic process in veins (such as deep venousthrombosis, pulmonary embolism) or arteries (e.g., stroke, myocardial infarction) or a known genetic component (homozygous), venous